Demand for Male Infertility and Impact of COVID-19……..
The global male
infertility market size is
expected to reach USD 5.03 billion by
2027, expanding at a CAGR of 4.7%
over the forecast period, according to a new report by Grand View Research,
Inc. Advancements in diagnostic tests and increasing infertility in males are
some of the major factors driving the market for male infertility. In addition,
lifestyle-associated diseases causing infertility, rising obesity, and growing
aging population are likely to boost the market growth during the forecast
period. In U.S., one-third of infertility cases are due to female factors, one
third due to male factors, and the remaining one third is unknown.
DNA fragmentation technique emerged
the largest test segment in the market in 2020 and is expected to maintain its
lead during the forecast period. Increasing adoption in developed countries and
high cost due to higher sensitivity and reliable analysis of sperm DNA
integrity are the key factors driving the segment.
On the basis of treatment, the
Assisted Reproductive Technology (ART) and Varicocele Surgery segment dominated
the market for male infertility in 2020 due to its high success rate.
Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are
the most commonly used ARTs. Medications include hormonal therapy and
corticosteroids, however they are effective in very few cases.
Partnerships and agreements among key
manufacturers are expected to boost the market growth in the coming years. For
instance, in July 2020, Vitrolife entered into a collaboration with Prime Tech
for the development and exclusive marketing of the Piezo technique, for
improved Intracytoplasmic Sperm Injection (ICSI) procedure in human IVF
globally except Malaysia, Thailand, and Japan. Additionally, Vitrolife will
initiate the regulatory approval procedures in various markets for the future
commercialization of the technology.
To Request Sample Copy of this report, click the link:
Further key findings from the study
suggest:
·
Based on test, DNA
fragmentation technique dominated the market in 2020 and is estimated to
witness significant growth over the forecast period
·
Oxidative stress analysis test
is gaining popularity due to the accurate determination of reactive oxygen
species. In March 2018, Aytu BioScience, Inc. received registration from
COFEPRIS in Mexico for MiOXSYS System, which is used for diagnosing male
infertility
·
Europe dominated the male
infertility market in 2020 and is expected to maintain its lead during the forecast
period due to high adoption of costlier treatment, strong diagnosis rate, and
increased awareness
·
Asia Pacific is projected to
witness substantial growth over the forecast period owing to increasing
investment by several clinics and pharmaceutical companies and growing
healthcare expenditure
·
Some key players of the market
are Bayer Healthcare, Inc.; EMD Sereno; Aytu BioScience, Inc.; Halotech DNA SL;
Intas Pharmaceuticals Ltd.; Cadila Healthcare Ltd.; Andrology Solutions; and
SCSA diagnostics, Inc.
The global male infertility market
size was valued at USD 3.5 billion in 2020 and is estimated to expand at a CAGR
of around 4.7% over the forecast period. Increasing infertility rate across the
globe and adoption of assisted reproductive technologies (ARTs) are expected to
be drive the market for male infertility in the forthcoming years.
ARTs cover a wide spectrum of
infertility treatments and offer solutions for males facing problems, such as
low sperm count, abnormal sperm quality, and poor motility. Moreover, ARTs
offer a high success rate as compared to the medications. The market for male
infertility is expected to witness significant growth in future owing to
technological advancements in the field of assisted reproductive technologies.
Increase in the global prevalence of infertility is a
significant clinical problem. Around 8% to 12% of couples have to deal with the
problem of infertility worldwide. Of all cases, about 40% to 50% of cases is
due to male factor infertility. This may be due to one or combination of
factors, such as abnormal morphology, lower sperm concentration, and poor sperm
motility. Hence, increasing male infertility and growing awareness about the
same have further prompted the use of drugs, hormonal therapy, and ART.
Alcohol intake, smoking, obesity, stress, and lifestyle changes
are the some of the major factors that can be attributed to infertility in
males. According to the National Center for Health Statistics, the fertility
rate in males below 30 years has decreased globally by 15% from 2006 to 2010.
Continuous efforts in R&D are carried out for a better
understanding of the idiopathic world of infertility. Hence, companies are
investing in the development of devices for identifying the root cause and
targeted treatment. Furthermore, development and commercialization of hormonal
therapy is likely to drive the market for male infertility during the forecast
period.
Have any Query? Ask our Experts:
Grand View Research has segmented the global male
infertility market based on test, treatment,:
Male Infertility Test Outlook (Revenue, USD
Million, 2015 - 2027)
·
DNA Fragmentation Technique
·
Oxidative Stress Analysis
·
Microscopic Examination
·
Sperm Agglutination
·
Computer Assisted Semen Analysis
·
Sperm Penetration Assay
·
Others
Male Infertility Treatment Outlook
(Revenue, USD Million, 2015 - 2027)
·
Assisted Reproductive Technology and
Varicocele Surgery
·
Medication
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment